3 completed, 2 recruiting, 1 active not recruiting, 1 withdrawn. 3 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Deoxycytidine: new trials by email Literature Review of Deoxycytidine trials Research Report on Deoxycytidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nucleoside Therapy in Patients With Telomere Biology Disorders deoxycytidine, deoxythymidine - Telomere Biology Disorders, Dyskeratosis Congenita | Phase 1 | Recruiting | Suneet Agarwal | 36 | 2025-09-29 | 2026-08-04 |
| A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) MT1621 - Thymidine Kinase 2 Deficiency | Phase 3 | Withdrawn | Zogenix MDS, Inc. | 2022-09-30 | 2023-09-01 | |
| Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome deoxycytidine and deoxythymidine - Mitochondrial Diseases, Mitochondrial Encephalomyopathy | Phase 2 | Recruiting | Kenneth Myers, MD | 200 | 2021-10-18 | 2026-10-19 |
| An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency doxecitine and doxribtimine - Thymidine Kinase 2 Deficiency | Phase 2 | Completed | UCB BIOSCIENCES, Inc. | 47 | 2019-07-05 | 2026-09-08 |
| A RETROspective Study of Patients With TK2d dC/dT - Thymidine Kinase 2 (TK2) | Completed | Zogenix MDS, Inc. | 38 | 2018-11-19 | 2023-09-01 | |
| Treatment of TK2 Deficiency With Thymidine and Deoxycytidine Thymidine - Mitochondrial DNA Depletion Syndrome 2 Myopathic Type, Thymidine Kinase 2 Deficiency | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 23 | 2017-05-16 | 2026-01-28 |
| High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies cytarabine, deoxycytidine - Drug/Agent Toxicity by Tissue/Organ, Leukemia | Phase 1 | Completed | Virginia Commonwealth University | 15 | 1995-02-01 | 2015-12-14 |
Mitochondrial Diseases (3) · Muscle Weakness (3) · Muscular Atrophy (2) · Blast Crisis (1) · Blepharoptosis (1) · Bone Marrow Failure Disorders (1) · Burkitt Lymphoma (1) · Deglutition Disorders (1) · Drug-Related Side Effects and Adverse Reactions (1) · Dyskeratosis Congenita (1) · Hodgkin Disease (1) · Hoyeraal Hreidarsson syndrome (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1)
Zogenix MDS, Inc. (2) · Columbia University (1) · Kenneth Myers, MD (1) · Suneet Agarwal (1) · UCB BIOSCIENCES, Inc. (1) · Virginia Commonwealth University (1)
United States (5) · Israel (2) · Spain (2) · Canada (1)
Helen Reed, MD, MPH (1) · Kenneth Alexis MD Myers, MD PhD FRCPC (1) · Michio Hirano, MD (1) · Steven Grant, MD (1)
PMID 33246973, PMID 11182283, PMID 12013896, PMID 12508073, PMID 12771225, PMID 12826641, PMID 15090651, PMID 15684706, PMID 16621917, PMID 16971696, PMID 16971699, PMID 17080429, PMID 17353390, PMID 17483096, PMID 17486094, PMID 17549623, PMID 18238797, PMID 18467430, PMID 18546365, PMID 19103785, PMID 19125351, PMID 19138848, PMID 19192035, PMID 19667227, PMID 19766516, PMID 19889013, PMID 20301762, PMID 20301791, PMID 20329599, PMID 20444604, PMID 21483760, PMID 21774628, PMID 21855607, PMID 22084276, PMID 22176657, PMID 22608879, PMID 22711161, PMID 23168274, PMID 23169334, PMID 23230576, PMID 23385875, PMID 23714749, PMID 23817075, PMID 23932787, PMID 245993, PMID 24708634, PMID 24968719, PMID 24985751, PMID 25857492, PMID 26342080
2018 (1), 2023 (1), P30CA016059 (1)